{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:13:49Z","timestamp":1789755229049,"version":"4.0.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled terminal complement activation and subsequent intravascular hemolysis (IVH). C5 inhibitors prevent membrane attack complex formation, but patients may experience extravascular hemolysis (EVH) and continue to require blood transfusions. Danicopan, an oral proximal complement inhibitor of alternative pathway factor D (FD), is designed to control IVH and EVH. In a phase 2 dose-finding trial, eculizumab-treated transfusion-dependent patients with PNH (n = 12) received danicopan, 100 to 200 mg thrice daily, in addition to their eculizumab regimen for 24 weeks. End points included hemoglobin (Hgb) change vs baseline at week 24 (primary), reduction in blood transfusions, and patient-reported outcomes. Safety, tolerability, and pharmacokinetics\/pharmacodynamics were measured. Twelve patients received \u22651 danicopan dose; 1 patients discontinued from a serious adverse event deemed unlikely related to danicopan. Eleven patients completed the 24-week treatment period. Addition of danicopan resulted in a mean Hgb increase of 2.4 g\/dL at week 24. In the 24 weeks prior to danicopan, 10 patients received 31 transfusions (50 units) compared with 1 transfusion (2 units) in 1 patient during the 24-week treatment period. Mean Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score increased by 11 points from baseline to week 24. The most common adverse events were headache, cough, and nasopharyngitis. Addition of danicopan, a first-in-class FD inhibitor, led to a meaningful improvement in Hgb and reduced transfusion requirements in patients with PNH who were transfusion-dependent on eculizumab. These benefits were associated with improvement of FACIT-Fatigue. This trial was registered at www.clinicaltrials.gov as #NCT03472885.<\/jats:p>","DOI":"10.1182\/blood.2021011388","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T13:55:08Z","timestamp":1627394108000},"page":"1928-1938","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":76,"title":["Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab"],"prefix":"10.1182","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin G.","family":"Kulasekararaj","sequence":"first","affiliation":[{"name":"King\u2019s College Hospital-NHS Foundation Trust, NIHR\/Wellcome King\u2019s Clinical Research Facility, London, United Kingdom;"},{"name":"King\u2019s College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-5109","authenticated-orcid":false,"given":"Antonio M.","family":"Risitano","sequence":"additional","affiliation":[{"name":"Federico II University of Naples, Naples, Italy;"},{"name":"AORN Moscati, Avellino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Notaro","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera Universitaria Careggi, Firenze, Italy;"},{"name":"Instituto per lo Studio, la Prevenzione e la Rete Oncologica, Firenze, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Browett","sequence":"additional","affiliation":[{"name":"University of Auckland, Auckland, New Zealand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"Seoul St. Mary\u2019s Hospital, The Catholic University of Korea, Seoul, Republic of Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Huang","sequence":"additional","affiliation":[{"name":"Achillion, Inc., a wholly-owned subsidiary of Alexion Pharmaceuticals, Inc., New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Geffner","sequence":"additional","affiliation":[{"name":"Achillion, Inc., a wholly-owned subsidiary of Alexion Pharmaceuticals, Inc., Blue Bell, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-1255","authenticated-orcid":false,"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2021111816211791800_B1","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat Rev Dis Primers."},{"issue":"2","key":"2021111816211791800_B2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2141.1999.01325.x","article-title":"Genotypic, immunophenotypic and clinical features of Thai patients with paroxysmal nocturnal haemoglobinuria","volume":"105","author":"Pramoonjago","year":"1999","journal-title":"Br J Haematol."},{"issue":"1","key":"2021111816211791800_B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI114172","article-title":"Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria","volume":"84","author":"Holguin","year":"1989","journal-title":"J Clin Invest."},{"issue":"1","key":"2021111816211791800_B4","first-page":"1","article-title":"Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers","volume":"71","author":"Meri","year":"1990","journal-title":"Immunology."},{"issue":"19","key":"2021111816211791800_B5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N Engl J Med."},{"issue":"4","key":"2021111816211791800_B6","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood."},{"issue":"6","key":"2021111816211791800_B7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med."},{"issue":"12","key":"2021111816211791800_B8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med."},{"issue":"11","key":"2021111816211791800_B9","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol."},{"issue":"1","key":"2021111816211791800_B10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol."},{"issue":"17","key":"2021111816211791800_B11","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood."},{"issue":"4","key":"2021111816211791800_B12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica."},{"key":"2021111816211791800_B13","first-page":"3471","article-title":"Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome","volume":"130","author":"McKinley","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2021111816211791800_B14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.seminhematol.2018.05.014","article-title":"C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications","volume":"55","author":"Notaro","year":"2018","journal-title":"Semin Hematol."},{"issue":"4","key":"2021111816211791800_B15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3324\/haematol.2009.017848","article-title":"Paroxysmal nocturnal hemoglobinuria and eculizumab","volume":"95","author":"Luzzatto","year":"2010","journal-title":"Haematologica."},{"issue":"11","key":"2021111816211791800_B16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.imbio.2012.07.014","article-title":"Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders","volume":"217","author":"Risitano","year":"2012","journal-title":"Immunobiology."},{"key":"2021111816211791800_B17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front Immunol."},{"issue":"11","key":"2021111816211791800_B18","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood.V112.11.3441.3441","article-title":"Modification of the eculizumab dose to successfully manage intravascular breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria","volume":"112","author":"Kelly","year":"2008","journal-title":"Blood."},{"issue":"5","key":"2021111816211791800_B19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood."},{"issue":"7","key":"2021111816211791800_B20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2015-02-625871","article-title":"Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria","volume":"126","author":"Lin","year":"2015","journal-title":"Blood."},{"issue":"1","key":"2021111816211791800_B21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-017-0496-x","article-title":"Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes","volume":"10","author":"Sica","year":"2017","journal-title":"J Hematol Oncol."},{"issue":"25","key":"2021111816211791800_B22","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.2174\/0929867326666191001130342","article-title":"Discovery and development of the oral complement factor D inhibitor danicopan (ACH-4471)","volume":"27","author":"Wiles","year":"2020","journal-title":"Curr Med Chem."},{"issue":"3","key":"2021111816211791800_B23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3324\/haematol.2016.153312","article-title":"Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome","volume":"102","author":"Yuan","year":"2017","journal-title":"Haematologica."},{"issue":"3","key":"2021111816211791800_B24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol."},{"key":"2021111816211791800_B25","article-title":"Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria","author":"Risitano","journal-title":"Haematologica."},{"issue":"2","key":"2021111816211791800_B26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.10245","article-title":"Fatigue in cancer patients compared with fatigue in the general United States population","volume":"94","author":"Cella","year":"2002","journal-title":"Cancer."},{"issue":"5","key":"2021111816211791800_B27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2013.093161","article-title":"Baseline characteristics and disease burden\u00a0in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry","volume":"99","author":"Schrezenmeier","year":"2014","journal-title":"Haematologica."},{"issue":"6","key":"2021111816211791800_B28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 Study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood."},{"issue":"6","key":"2021111816211791800_B29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 Study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood."},{"issue":"26","key":"2021111816211791800_B30","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1182\/blood-2011-12-398792","article-title":"The complement receptor 2\/factor H fusion\u00a0protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from\u00a0complement-mediated hemolysis and\u00a0C3 fragment","volume":"119","author":"Risitano","year":"2012","journal-title":"Blood."},{"issue":"15","key":"2021111816211791800_B31","first-page":"2205","article-title":"Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"129","author":"Risitano","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2021111816211791800_B32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2013.090001","article-title":"Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Rondelli","year":"2014","journal-title":"Haematologica."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/138\/20\/1928\/1845788\/bloodbld2021011388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/138\/20\/1928\/1845788\/bloodbld2021011388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T12:15:45Z","timestamp":1637237745000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/20\/1928\/476463\/Phase-2-study-of-danicopan-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":32,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,11,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021011388","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}